A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

374

Participants

Timeline

Start Date

April 11, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

April 1, 2027

Conditions

Advanced Malignant Solid Tumours

Interventions

DRUG

JS212 for Injection

JS212 for Injection is administered on the first day of the first cycle and every 3 weeks thereafter.

Trial Locations (1)

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER